SVA selected Shanghai Government - CHINA

Sinovac Biotech announced that it was selected by the Shanghai Government to supply its inactivated hepatitis A vaccine, Healive, to the public market of Shanghai . Out of the five vaccine manufacturers that participated in the bidding process, the Shanghai Government awarded Sinovac the entire hepatitis A vaccine purchase order, valued at RMB 20.6 million , or approximately $3M . Pursuant to the agreement, Sinovac will supply Healive over the next twelve months.